Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Staphylococcus lugdunensis is a coagulase-negative staphylococcus belonging to the human commensal cutaneous flora, and has been little studied in the field of prosthetic joint infections. However, it shares many virulence traits with Staphylococcus aureus, including many adhesins and its ability to form biofilm, and the few series of cases reports a significant failure rate.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prothestic joint infection due to Staphylococcus lugdunensis | Patients having had a prosthetic joint infection with Staphylococcus lugdunensis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prothestic joint infection due to Staphylococcus lugdunensis | Other | description of prosthetic joint infection with Staphylococcus lugdunensis |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of PJI infection with Staphylococcus lugdunensis | proportion of patients having PJI infection with Staphylococcus lugdunensis, alone or with other bacteria | between 2010 and 2020 |
| Description of PJI infection with Staphylococcus lugdunensis : type | type of PJI : knee or hip prosthesis | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| Description of PJI infection with Staphylococcus lugdunensis : evolution | evolution of PJI :evolution between prosthesis placement and the onset of symptoms, gateway to infection | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| Description of patients with PJI infection due to Staphylococcus lugdunensis | type of patients: age, CMI | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| Description of patients with PJI infection due to Staphylococcus lugdunensis : follow up | duration of the follow up of patients | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| Description of patients with PJI infection due to Staphylococcus lugdunensis : medical treatment | description and duration of antibiotics | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients having had IPA due to Staphylococcus lugdunensis
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon | Lyon | 69004 | France |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013203 | Staphylococcal Infections |
| ID | Term |
|---|---|
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| Description of patients with PJI infection due to Staphylococcus lugdunensis : surgical treatment | description of surgery performed : DAIR, one-step exchange, two-step exchange | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| rate of treatment failure | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |